Future market insights has announced the addition of the “Dry Powder Inhaler Market: Global Industry Analysis 2012 – 2016 and Opportunity Assessment; 2017 – 2027" report to their offering.
Valley Cottage, NY -- (SBWIRE) -- 01/15/2018 -- Globally there is an increasingly urgent need for effective treatment options for inhalation. Increasing prevalence of the chronic obstructive pulmonary diseases globally has led to the advent of a large number of inhalation devices. Dry powder inhalers refers to a device which helps in an effective delivery of medication to the lungs in the form of dry powder. The dry powder inhalers are portable and easy to carry which makes them a popular choice amongst respiratory disease patients. Moreover, they are variable in design due to which they fit in a majority of different requirements of the patients. Dry powder inhalers in the healthcare device market are expected to expand at a healthy CAGR attributed to an increasing number of respiratory tract infection and diseases contributed by unhealthy lifestyle globally.
Global Dry Powder Inhaler Market: Dynamics
Accurate dosing is a prime concern for patients suffering from respiratory diseases. Dry powder inhalers also referred to as metered dose inhalers and they ensure proper dosing. Demographic changes and a rising aging population is leading to an increased demand for devices for inhalation which is anticipated to drive the global dry powder inhalers market. Also, a large number of medicines for diseases today are being designed for inhalation which is further expected to drive the global dry powder inhalers market. One factor restraining the growth of the dry powder inhalers is that they are moisture sensitive which leads to an increased risk of the medicine losing its properties. Also, there is strong competition from other types of inhalation methods such as nebulizers and electric pumps. There are ample opportunities of growth for the global dry powder inhalers market wherein the dry powder inhalers manufacturers are using new techniques such as the computational fluid dynamics to develop a whole new generation of dry powder inhalers.
Request Report Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-5150
Global Dry Powder Inhaler Market: Segmentation
The global dry powder inhalers market is segmented on the basis of product type, application type, end use, and geography.
On the basis of product type, the global dry powder inhaler market is segmented into
Single dose dry powder inhaler
Multi dose dry powder inhaler
On the basis of application, the global dry powder inhalers market is segmented into
On the basis of end use, the global dry powder inhalers market is segmented into
Clinics & Hospitals
Home & Personal Care
Visit For TOC@ https://www.futuremarketinsights.com/toc/rep-gb-5150
Global Dry Powder Inhaler Market: Regional Outlook
On the basis of geography, the global dry powder inhalers market is segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is expected to lead the global dry powder inhalers market as the region is marked by the presence of countries which are early adopters of the healthcare technology. North America dry powder inhalers market is followed by Europe wherein the market is expected to increase due to a well-established pharmaceutical and medical devices market. The region is also represented by rising healthcare investment. Asia Pacific region is expected to expand at the highest CAGR due to rising disposable income of the population especially in economy such as India. Economies such as India and China are also market by an increasing geriatric population further bolstering the demand of dry powder inhalers in the region.
Global Dry Powder Inhaler Market: Key Players
Some of the key players operating in the global dry powder inhalers market are Catalent, Inc.,Cipla Inc., Hovione FarmaCiencia SA. GlaxoSmithKline Plc., AstraZeneca Plc., Teicos Pharma Ltd, Bespak Europe Ltd, Presspart Manufacturing Ltd., Luckys Pharma, Beximco Pharma Ltd., and SRS Pharmaceuticals Pvt. Ltd.